Fna bx w/ct gdn 1st les
CPT code 10009 covers a CT-guided fine needle aspiration (FNA) biopsy of the first lesion, where a radiologist uses CT imaging to guide a thin needle into a suspicious mass to extract tissue samples for laboratory analysis.
This calculator gives a typical-case estimate using standard Medicare modifier rules. Actual payment depends on payer policies, documentation, code-specific CMS status indicators, and locality. Verify before billing.
RVU breakdown
Conversion factor: 32.3465 · Source: CMS MPFS RVU25A · Confidence: High
NCCI bundling edits
Loading bundling edits…
Billing tips
Always verify place of service and bill with appropriate modifier 26/TC split in facility settings versus global billing in non-facility settings
Impact: $301.80 difference between settings - incorrect POS coding can result in overpayment recovery or underpayment
Use add-on code 10010 for each additional lesion biopsied during the same session with CT guidance, never bill 10009 twice
Impact: 10010 adds approximately $102-156 per additional lesion; billing 10009 multiple times will trigger bundling edits and denials
Document real-time CT guidance explicitly in the operative note, including number of CT images obtained, confirmation of needle position, and adjustments made under CT visualization
Impact: Absence of CT guidance documentation can result in downcoding to non-guided FNA (10021) with $250+ payment reduction
Submit pathology reports with the claim for initial submission when possible, especially for Medicare and commercial payers with prepayment review programs
Impact: Reduces audit requests by 40-60% and accelerates payment by 10-15 days on average
Check LCD/NCD coverage requirements for specific anatomic sites; some Medicare contractors require prior authorization for certain indications
Impact: Prevents denials for non-covered services; retroactive denials can cost the full $405.63 if authorization not obtained
Bill the appropriate E/M service separately with modifier 25 only when a significant, separately identifiable evaluation occurs beyond the decision for biopsy
Impact: Can add $75-200 when appropriately documented, but inappropriate use triggers audits and modifier 25 scrutiny
Real billers contribute denial patterns and appeal strategies for this code. Once 5+ reports come in, you’ll see live aggregated data here — the only place this exists, free.
Get the free Revenue Protection Toolkit — the denial triggers, modifier pitfalls, and bundling conflicts that quietly cost you reimbursement. Instant download.
Help build the field knowledge
MedPayIQ gets smarter as billers contribute. If you've had this code denied, share what happened so others learn from it. Anonymous, no patient info.